Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026)

Anika Therapeutics (ANIK) has reported Income from Continuing Operations for 17 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 170.3% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was -$1.5 million, a 89.77% increase from a year earlier, with the FY2025 full-year figure at -$8.3 million, up 18.23% from the prior year.
• Income from Continuing Operations was $3.3 million for Q2 2026 at Anika Therapeutics, up from -$5.1 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $16.2 million in Q4 2023 and troughed at -$10.3 million in Q1 2023.
• A 5-year average of -$1.3 million and a median of -$2.9 million in 2022 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 411.38% in 2022, down 853.99% in 2022.
• Over 5 years, Income from Continuing Operations stood at $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then plunged by 123.48% to -$3.8 million in 2024, then surged by 191.76% to $3.5 million in 2025, then slipped by 5.94% to $3.3 million in 2026.
• The last three Income from Continuing Operations figures came in at $3.3 million (Q2 2026), -$5.1 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.